Ad-hoc | 6 February 2001 08:30

Ad hoc-Service: aap Implantate AG english

Ad-hoc announcement precessed and sent by DGAP. The sender is solely responsible for the contents of this announcement. ——————————————————————————– FDA clears for marketing new bone cement from aap subsidiary Coripharm The aap-subsidiary Coripharm Medizinprodukte GmbH & Co, a specialist for biomaterials, has achieved an important milestone in its business field bone cements. The U.S. Food and Drug Administration (FDA) has cleared for marketing the bone cement VersaBond(r), developed by Coripharm GmbH & Co. KG for its US- sales partner, the Orthopedic Division of Smith & Nephew, Inc. Coripharm GmbH & Co. KG is a wholly-owned subsidiary of Berlin-based German company aap Implantate AG. The bone cement is manufactured by Coripharm GmbH & Co. KG in Dieburg, Germany. Smith & Nephew Inc. is sole distributor in the U.S. and worldwide. In addition, the US-company has integrated into its product portfolio as sole distributor worldwide the MixOR(r) cementing technique, developed exclusively by Coripharm GmbH & Co. KG. VersaBond(r) bone cement is designed for use in joint replacements, especially hip and knee replacements, when a prosthesis has to be cemented. Cementing the prosthesis fixes the artificial-implant parts mechanically, enabling the patient to put weight or strain on the affected area right away. Specially designed for use with VersaBond(r) bone cement, Coripharm has developed a new vacuum cementing system. It is also manufactured at Coripharm GmbH & Co. KG’s production facilities exclusively for Smith & Nephew, Inc. aap Implantate AG, a leading German company in the biomedical implant field, estimates the annual volume of the global market for bone cement and cementing technique at EUR 300 mio. If you have any queries, please contact: aap Implantate AG aap Implantate AG Bruke Seyoum Alemu Gabriele Voßkühler Member of the Board of Management Investor Relations Finance and Information Technology Lorenzweg 5 Lorenzweg 5 12099 Berlin 12099 Berlin Tel: +49 (0)30 / 750 19-170 Tel: +49 (0)30 / 750 19-133 Fax: +49 (0)30 / 750 19-111 Fax: +49 (0)30 / 750 19-111 end of Ad hoc-announcement, (c) DGAP 06.02.2001 ———————————————————————– WKN:506660; Index: Listed:Neuer Markt Frankfurt; Freiverkehr in Berlin, Bremen, Düsseldorf, Hamburg, Hannover, München und Stuttgart 060830 Feb 01